RF ablation sets sights on breast cancer

Article

Early research on radio-frequency ablation (RFA) in the breast shows promising results, prompting hope that the procedure may one day offer an alternative to surgical resection for small tumors.

Early research on radio-frequency ablation (RFA) in the breast shows promising results, prompting hope that the procedure may one day offer an alternative to surgical resection for small tumors.

Using RFA to treat tumors in 26 patients with biopsy-proven T1 and T2 breast carcinoma, researchers in Italy and at the University of Texas M.D. Anderson Cancer Center aimed for complete ablation and a 5-mm margin. They achieved complete tumor necrosis in 25 of 26 patients, or 96%.

Traditional surgery, such as lumpectomy, usually takes about an hour. Researchers reported a mean treatment time for two-phase RFA of 15 minutes and 23 seconds.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.